Native Tumor Microenvironment Preserved

Human tumor tissues are the most relevant models for cancer drug development. Unlike organoids, patient-derived explants maintain native cancer, immune and fibroblast cells. However, ex vivo assays have limited viability and throughput. MISO Chip's tumor explant platform overcomes these barriers, maximizing insights from scarce human tissues. Drugs targeting the tumor microenvironment can now be tested with MISO Chip’s platform to validate their mechanism of action, efficacy and provide a strong preclinical proof-of-concept.

Cytokine Response Assay

MISO Chip’s Cytokine Response Assay allows scientists to study the impact of their drug candidate on patient-derived 3D microtissues called Micro-Dissected Tumors (MDT). With a panel of up to 275 cytokines & chemokines measured from the explants’ supernatant, this assay deciphers the immune cells response (myeloid, lymphoid) in a relevant tumor context maintaining original cell-cell interactions of immune, fibroblast and cancer cells. The results support mechanism of action studies and can be complemented with pathway analysis and pharmacodynamic (PD) studies at the tissue level using MISO Chip proprietary paraffin-embedding technique and spatial biology.

Assay Principles

Freshly cut MDTs from tumor tissues are seeded into the MISO Chip Platform for ex vivo culture. After a 48-hour rest period, MDTs are incubated another 48 hours in the presence or absence of test compounds. Before and after treatment, supernatant is collected for multiplex cytokine analysis.